Hayato Yamamoto

8PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological modellingCardiology (incl. cardiovascular diseases)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 14, 2026
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.

|Aug 15, 2026
Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real-World Cohorts.

|Feb 15, 2023
Can Erectile Dysfunction Severity Predict Major Adverse Cardiovascular Events in Men Undergoing Dialysis? A Prospective Cohort Study.

Naoki Fujita, Masaki Momota, Yusuke Ozaki

|Jul 06, 2022
Association between Aortic Calcification Burden and the Severity of Erectile Dysfunction in Men Undergoing Dialysis: A Cross-Sectional Study.

Naoki Fujita, Shingo Hatakeyama, Masaki Momota

|May 16, 2022
Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.

Naoki Fujita, Shingo Hatakeyama, Masaki Momota

|Sep 22, 2021
Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.

Tohru Yoneyama, Hayato Yamamoto, Mihoko Sutoh Yoneyama

Pageof 2

Frequent Collaborators

7 joint publications

Shingo Hatakeyama

5 joint publications

Naoki Fujita

5 joint publications

Tohru Yoneyama

5 joint publications

Yuki Tobisawa